Meeting
2012 ASCO Annual Meeting
A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.
Authors
Joyce Leta Steinberg
Astellas Pharma Global Development, Deerfield, IL
Joyce Leta Steinberg , Agop Y. Bedikian , D. Scott Ernst , Bartosz Chmielowski , Bruce Redman , Anne Therese Keating , Fei Jie , Caroline Chen , Jeffrey S. Weber , Ragini Reiney Kudchadkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Clinical Trial Registration Number
NCT01009775
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8587)
DOI
10.1200/jco.2012.30.15_suppl.8587
Abstract #
8587
Poster Bd #
37E
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
First Author: Howard Kaufman
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
First Author: Maria Constantinou
Poster
2017 ASCO Annual Meeting
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
First Author: Jason Alan Chesney